Form 8-K - Current report:
SEC Accession No. 0001193125-20-177678
Filing Date
2020-06-24
Accepted
2020-06-24 16:21:15
Documents
18
Period of Report
2020-06-24
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d946491d8k.htm   iXBRL 8-K 43554
2 EX-4.1 d946491dex41.htm EX-4.1 64470
3 EX-4.2 d946491dex42.htm EX-4.2 64965
4 EX-4.3 d946491dex43.htm EX-4.3 65175
5 EX-4.4 d946491dex44.htm EX-4.4 65194
6 EX-5.1 d946491dex51.htm EX-5.1 6151
  Complete submission text file 0001193125-20-177678.txt   548781

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA mrk-20200624.xsd EX-101.SCH 5138
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE mrk-20200624_def.xml EX-101.DEF 14803
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrk-20200624_lab.xml EX-101.LAB 24957
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrk-20200624_pre.xml EX-101.PRE 15966
11 EXTRACTED XBRL INSTANCE DOCUMENT d946491d8k_htm.xml XML 9460
Mailing Address 2000 GALLOPING HILL ROAD KENILWORTH NJ 07033
Business Address 2000 GALLOPING HILL ROAD KENILWORTH NJ 07033 908-740-4000
Merck & Co., Inc. (Filer) CIK: 0000310158 (see all company filings)

EIN.: 221918501 | State of Incorp.: NJ | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-06571 | Film No.: 20985745
SIC: 2834 Pharmaceutical Preparations